Bulk Pharmaceutical API Sources for afatinib dimaleate

Bulk Pharmaceutical API Sources for afatinib dimaleate

Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE		HY-10261A
AbaChemScene		CS-1329
CEGChem		QC-11139
labseeker		SC-87788

AFATINIB DIMALEATE BULK ACTIVE PHARMACEUTICAL INGREDIENT SOURCES

Last updated: February 19, 2026

This report identifies key bulk active pharmaceutical ingredient (API) suppliers for afatinib dimaleate. It details manufacturing capabilities, regulatory standing, and capacity, providing critical intelligence for procurement and supply chain strategy.

WHAT IS AFATINIB DIMALEATE?

Afatinib dimaleate is an irreversible tyrosine kinase inhibitor (TKI) used in the treatment of specific types of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. It functions by blocking signaling pathways that promote cancer cell growth and survival. The drug is marketed under the brand name Gilotrif by Boehringer Ingelheim.

PRIMARY MANUFACTURERS AND SUPPLIERS OF AFATINIB DIMALEATE API

The production of afatinib dimaleate API is concentrated among a limited number of specialized manufacturers. These entities typically possess advanced chemical synthesis capabilities and adhere to stringent Good Manufacturing Practices (GMP).

• Boehringer Ingelheim: As the originator and brand holder, Boehringer Ingelheim manufactures afatinib dimaleate API internally. This internal manufacturing provides direct control over quality, supply, and intellectual property. Their production facilities operate under strict regulatory oversight from global health authorities including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Specific details on their API production capacity are proprietary.

• Contract Development and Manufacturing Organizations (CDMOs): Several CDMOs globally are capable of producing afatinib dimaleate API, particularly for generic manufacturers or companies seeking secondary supply chains. These CDMOs are subject to rigorous auditing by their clients and regulatory bodies.

  • Lonza: Lonza is a significant player in the pharmaceutical API manufacturing space. They have broad expertise in complex small molecule synthesis and operate multiple GMP-certified facilities. While Lonza does not publicly list afatinib dimaleate as a standard catalog product, their capabilities for custom synthesis and large-scale API production position them as a potential supplier. Their regulatory track record is extensive, with numerous FDA and EMA site approvals [1].

  • WuXi AppTec: WuXi AppTec offers comprehensive API development and manufacturing services. They have demonstrated expertise in various therapeutic areas and possess the infrastructure for kilogram to multi-ton scale production. Their facilities are inspected by major regulatory agencies. For afatinib dimaleate, WuXi AppTec would likely engage in custom synthesis projects based on specific client requirements and intellectual property considerations. Their capacity is scalable, accommodating projects from early development to commercial launch [2].

  • Piramal Pharma Solutions: Piramal Pharma Solutions provides end-to-end API manufacturing solutions. They are known for their process development expertise and manufacturing scale-up capabilities. Piramal operates multiple cGMP facilities globally, audited by international regulatory authorities. They are equipped to handle complex synthetic routes and multi-step chemical processes required for afatinib dimaleate. Specific production volumes are project-dependent.

  • Divi's Laboratories: Divi's Laboratories is a large-scale API manufacturer based in India. They specialize in high-volume production of APIs. While their product portfolio is extensive, direct public listing of afatinib dimaleate is not common. However, their operational scale, robust quality systems, and approvals from international regulatory agencies suggest capability for such complex molecules, often manufactured under contract. Divi's focus on complex chemistry and large-scale production makes them a potential candidate for supplying intermediates or the final API through custom manufacturing agreements [3].

MANUFACTURING PROCESS AND CHALLENGES

The synthesis of afatinib dimaleate is a multi-step chemical process that requires specialized expertise and infrastructure. Key considerations include:

• Chiral Purity: Afatinib contains chiral centers, necessitating stereoselective synthesis or chiral resolution to ensure the desired enantiomer is produced with high purity. Impurities, including enantiomeric impurities, can affect efficacy and safety profiles.
• Process Scalability: Transitioning from laboratory-scale synthesis to commercial manufacturing requires robust process development to maintain yield, purity, and cost-effectiveness. Optimization of reaction conditions, solvent selection, and purification methods is critical.
• Impurity Profiling and Control: Rigorous control and characterization of process-related impurities and degradants are essential to meet regulatory requirements. This involves the development and validation of sensitive analytical methods.
• Salt Formation: The dimaleate salt form requires precise control over stoichiometry and crystallization conditions to ensure consistent particle size, polymorphic form, and dissolution characteristics.
• Regulatory Compliance: Manufacturing facilities must comply with current Good Manufacturing Practices (cGMP) as defined by regulatory bodies like the FDA and EMA. This includes stringent quality control, quality assurance, and documentation practices.

REGULATORY LANDSCAPE

API suppliers for afatinib dimaleate must demonstrate compliance with international pharmaceutical regulations. Key aspects include:

• Drug Master Files (DMFs): Suppliers typically file DMFs with regulatory agencies (e.g., FDA, EMA). These confidential documents contain detailed information about the manufacturing process, facilities, controls, and quality of the API. Pharmaceutical companies reference these DMFs in their drug product applications.
• Facility Inspections: Manufacturing sites are subject to regular inspections by regulatory authorities to ensure ongoing compliance with cGMP. Successful inspection outcomes are critical for API supply.
• ICH Guidelines: Adherence to International Council for Harmonisation (ICH) guidelines, particularly those related to quality (e.g., ICH Q7 for API GMP), impurity testing (ICH Q3A/B/C), and stability testing (ICH Q1A-F), is mandatory.
• Supply Chain Security: Pharmaceutical companies increasingly demand transparency and security throughout the API supply chain to mitigate risks of counterfeiting and ensure product integrity.

CAPACITY AND SCALABILITY

The demand for afatinib dimaleate API is influenced by the prescribing patterns for EGFR-mutated NSCLC and the competitive landscape of targeted therapies.

• Boehringer Ingelheim's Internal Capacity: As the originator, Boehringer Ingelheim maintains sufficient internal capacity to meet global demand for the branded product. Details are proprietary.
• CDMO Capacity: CDMOs have scalable infrastructure capable of producing APIs from kilogram to multi-ton quantities. Their ability to allocate resources and manage complex multi-step syntheses is crucial. For instance, a typical commercial batch size could range from tens to hundreds of kilograms, depending on market demand and the dosage strength of the final drug product. The overall global capacity for afatinib dimaleate API among CDMOs is sufficient to support both innovator and generic market needs, contingent on securing manufacturing slots and successful technology transfer.

KEY CONSIDERATIONS FOR PROCUREMENT

Companies seeking to procure afatinib dimaleate API should evaluate suppliers based on the following criteria:

• Quality and Regulatory Compliance: Verify GMP certification, inspection history, and the completeness and acceptance of filed DMFs.
• Manufacturing Expertise: Assess the supplier's experience with complex multi-step synthesis, chiral chemistry, and impurity control.
• Capacity and Scalability: Ensure the supplier can meet current and projected future volume requirements.
• Supply Chain Reliability: Evaluate the supplier's risk management strategies, business continuity plans, and historical performance.
• Cost-Effectiveness: Negotiate pricing that reflects the complexity of the API and the supplier's manufacturing efficiency.
• Intellectual Property: Understand the IP landscape surrounding the API and ensure freedom to operate.

KEY TAKEAWAYS

• Boehringer Ingelheim is the primary internal manufacturer of afatinib dimaleate API for its branded product.
• Several global CDMOs possess the technical and regulatory capabilities to produce afatinib dimaleate API, including Lonza, WuXi AppTec, Piramal Pharma Solutions, and Divi's Laboratories.
• Manufacturing complexity centers on chiral purity, process scalability, impurity control, and salt formation.
• Strict adherence to cGMP and robust regulatory filings (e.g., DMFs) are essential for API suppliers.
• Procurement decisions should prioritize quality, regulatory standing, capacity, and supply chain reliability.

FREQUENTLY ASKED QUESTIONS

1. What is the typical lead time for securing a commercial supply of afatinib dimaleate API from a CDMO? Lead times can vary significantly but generally range from 6 to 18 months, encompassing process validation, analytical method transfer, and initial commercial batch production. This duration is dependent on the CDMO's current manufacturing schedule and the complexity of the technology transfer.

2. Are there publicly available lists of approved API suppliers for afatinib dimaleate? No, specific lists of approved API suppliers for afatinib dimaleate are not publicly available. Pharmaceutical companies maintain their own internal approved vendor lists based on rigorous qualification processes. Potential buyers must conduct due diligence on prospective manufacturers.

3. What are the primary analytical methods used to ensure the quality of afatinib dimaleate API? Key analytical methods include High-Performance Liquid Chromatography (HPLC) for assay and purity, Gas Chromatography (GC) for residual solvents, Mass Spectrometry (MS) for identification and impurity characterization, Nuclear Magnetic Resonance (NMR) for structural confirmation, and Karl Fischer titration for water content.

4. What is the significance of the "dimaleate" in afatinib dimaleate? The "dimaleate" refers to the salt form of afatinib. It is formed by reacting the afatinib base with maleic acid. This salt form is chosen to improve properties such as solubility, stability, and bioavailability of the active drug substance, facilitating formulation into oral dosage forms.

5. Can companies source intermediates for afatinib dimaleate API production, or is it only the final API? Companies can source both complex intermediates and the final API. For strategic supply chain management or cost optimization, some manufacturers may choose to procure key advanced intermediates from specialized suppliers and perform the final synthesis steps internally or with a different partner. The decision depends on factors such as in-house expertise, intellectual property considerations, and supplier capabilities.

CITATIONS

[1] Lonza. (n.d.). Small Molecules. Retrieved from https://www.lonza.com/products-services/pharma-biotech/drug-substance/small-molecules

[2] WuXi AppTec. (n.d.). API Development and Manufacturing. Retrieved from https://www.wuxiapptec.com/service/pharma/api-development-manufacturing/

[3] Divi's Laboratories. (n.d.). API Manufacturing. Retrieved from https://www.divislabs.com/api-manufacturing/